title: [Molecular characterization of breast cancer in clinical practice].
abstract: Breast cancer involves various types of tumors. The objective of this review was to provide a summary of the main methods currently available in clinical practice to characterize breast cancers at a molecular level and to discuss their prognostic and predictive values. Hormonal receptors expression and the HER2 status are prognostic markers and can also predict the response to targeted therapies. Their analysis through immunohistochemistry is systematical. Ki67 is an effective prognostic marker, but its reliability is debated because of its low reproducibility between laboratories and between pathologists. Commercial genomic signatures are all considered valid prognostic tools and may guide physicians to make therapeutic choices. These signatures are costly and should therefore be restricted to situations in which the use of chemotherapy remains equivocal.
authors.affiliation: Département de chirurgie, institut Curie, hôpital René-Huguenin, 35, rue Dailly, 92210 Saint-Cloud, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Zemmouri
authors.affiliation: Service de pathologie, institut Curie, hôpital René-Huguenin, 35, rue Dailly, 92210 Saint-Cloud, France.
authors.forename: D
authors.initials: D
authors.lastname: De Croze
authors.affiliation: Pôle de pathologie, génétique, immunologie, service de pathologie, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Vincent Salomon
authors.affiliation: Département de chirurgie, institut Curie, hôpital René-Huguenin, 35, rue Dailly, 92210 Saint-Cloud, France; EA 7285, risques cliniques et sécurité en santé des femmes et en santé périnatale, université de Versailles-St-Quentin-en-Yvelines, 2, avenue de la Source-de-la-Bièvre, 78180 Montigny-Le-Bretonneux, France.
authors.forename: R
authors.initials: R
authors.lastname: Rouzier
authors.affiliation: Département de chirurgie, institut Curie, hôpital René-Huguenin, 35, rue Dailly, 92210 Saint-Cloud, France; EA 7285, risques cliniques et sécurité en santé des femmes et en santé périnatale, université de Versailles-St-Quentin-en-Yvelines, 2, avenue de la Source-de-la-Bièvre, 78180 Montigny-Le-Bretonneux, France. Electronic address: clairebonneau1@gmail.com.
authors.forename: C
authors.initials: C
authors.lastname: Bonneau
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000235:genetics* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015203:Reproducibility of Results
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: Breast cancer; Cancer du sein; Classification moléculaire; Genomic signature; Molecular classification; Médecine de précision; Precision medicine; Signature génomique